Saira Sundus, MD
Endocrinology, Diabetes & Metabolism · Flint, MINPI 1265953988
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,796 of the $10,019 with a category attached, or 87.8%. It is spread thinly across 41 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,903, more than ten times the $237 reported in 2019.
Across 530 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Amgen$1K
- Corcept Therapeutics$936
- Xeris Pharmaceuticals, Inc.$914
- Novo Nordisk$702
- Lilly USA, LLC$485
- plus $4K from 35 others
What the payments were for
- Consulting fees$1,20012%
- Food & beverage$8,79688%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 33 | $1,826 |
| Amgen(2 entities) | 90 | $1,129 |
| Corcept Therapeutics | 53 | $936 |
| Xeris Pharmaceuticals, Inc. | 57 | $914 |
| Novo Nordisk | 80 | $702 |
| Lilly USA, LLC | 26 | $485 |
| Sanofi-aventis U.S. LLC | 13 | $338 |
| Medtronic | 9 | $279 |
| BETA Bionics, Inc. | 18 | $273 |
| AstraZeneca(2 entities) | 8 | $262 |
| Dexcom, Inc. | 13 | $248 |
| AbbVie | 13 | $239 |
| Boehringer Ingelheim | 12 | $227 |
| Insulet Corporation | 13 | $226 |
| Tandem Diabetes Care, Inc. | 9 | $206 |
| Recordati_rare_diseases_inc. | 7 | $178 |
| Radius Health, Inc. | 9 | $169 |
| Amneal Pharmaceuticals LLC | 8 | $163 |
| Pfizer | 6 | $163 |
| Ascendis Pharma Endocrinology Inc | 7 | $149 |
| Madrigal Pharmaceuticals | 5 | $123 |
| Neurocrine Biosciences, Inc. | 5 | $111 |
| Bayer | 5 | $110 |
| IBSA Pharma Inc. | 5 | $69 |
| Alvogen Inc | 3 | $53 |
| Kyowa Kirin, Inc. | 2 | $47 |
| Verity Pharmaceuticals Inc. | 2 | $46 |
| Antares Pharma, Inc. | 2 | $42 |
| EUSA Pharma (US) LLC | 2 | $41 |
| Ultragenyx Pharmaceutical Inc. | 2 | $40 |
| Mannkind Corporation | 2 | $35 |
| Nevro Corp. | 1 | $31 |
| Amphastar Pharmaceuticals, Inc. | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| Cequr Corporation | 2 | $20 |
| Halozyme Inc | 1 | $20 |
| GSK | 1 | $18 |
| Evoke Pharma, Inc. | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$1,200
- INPEN SMART INSULIN DELIVERY SYSTEM$128
- FARXIGA$125
- Korlym$114
- SOLIQUA 100/33$108
How this compares
$10,019 in reported general payments places this provider in the 75th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 608 | $906,986 |
| JardianceEmpagliflozin | 685 | $788,446 |
| MounjaroTirzepatide | 454 | $716,862 |
| TrulicityDulaglutide | 445 | $664,117 |
| RecorlevLevoketoconazole | 11 | $241,404 |
| JanuviaSitagliptin Phosphate | 92 | $115,250 |
| Tresiba Flextouch U-200Insulin Degludec | 86 | $101,823 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 501 | $96,244 |
| FarxigaDapagliflozin Propanediol | 83 | $91,501 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $60,306 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $56,247 |
| Humalog Kwikpen U-100Insulin Lispro | 157 | $56,191 |
| TradjentaLinagliptin | 51 | $51,172 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 91 | $50,164 |
| Novolog FlexpenInsulin Aspart | 164 | $46,114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $485 | $1,392,921935 claims |
| Novo NordiskOzempic, Novolog | $702 | $916,658637 claims |
| Boehringer IngelheimJardiance, Tradjenta | $227 | $839,618736 claims |
| Xeris Pharmaceuticals, Inc.Recorlev | $914 | $241,40411 claims |
| AstraZenecaFarxiga | $262 | $91,50183 claims |
| AmgenProlia | $1,129 | $31,89219 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $163 | $5,953546 claims |
| Sanofi-aventis U.S. LLCLantus | $338 | $3,57917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Flint
- Jamal HammoudFlint$386K
- Muhammad BaklehFlint$18K
- Abdallah DlewatiFlint$9K
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Eric LangerSterling Heights$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.